天天av福利整合五月天激情综合网视频播放资源，支持9i制作厂网页版入口手机在线点播，国产麻豆精品一区二区

Ming Y. Lim
Rating: 4.9 of 5
( out of 98 reviews )

Ming Y. Lim, MBBCh, MS

Languages spoken: English

Clinical Locations

Sugar House Health Center

Salt Lake City
801-581-2000

  • Dr. Ming Y. Lim is an Associate Professor in the Division of Hematology and Hematologic Malignancies at the University of Utah. She earned her medical degree at Cambridge University, England and completed her 2-year Foundation Training in the United Kingdom. She then completed residency in internal medicine at the Mayo Clinic Rochester and fellowship training in hematology and oncology at University of North Carolina at Chapel Hill. Her clinical interest lies in the field of hemostasis and thrombosis. Her research interest is focused on complications affecting people with congenital bleeding disorders, specifically persons with hemophilia with inhibitors and pregnant women with bleeding disorders.

    Dr. Lim is the Medical Director for the Utah Center for Bleeding & Clotting Disorders at University of Utah Health. Nationally, she serves as the Chair of the American Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Assessment Approval Committee, the Chair of the American Society of Hematology (ASH) Subcommittee on Stewardship and Systems-Based Hematology, and the Education Officer for the Hemostasis and Thrombosis Research Society (HTRS). She also serves on the National Bleeding Disorders Foundation (NBDF) Medical and Scientific Advisory Council (MASAC) and on the National Comprehensive Cancer Network (NCCN) Cancer-Associated Venous Thromboembolic Disease Panel.

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    Educational Commission for Foreign Medical Graduates
    National Certification Board for Anticoagulation Providers

    Patient Rating

    Rating: 4.9 out of 5
    4.9 /5
    ( out of 98 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    August 20, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    Very kind and caring

    July 09, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    The score of very good in your survey does not do justice to Dr. Lim. She deserves above a beyond and above category. She was very welcoming. I felt listened to and very much included in the treatment plan.

    July 02, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    She is an excellent physician.

    June 03, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    Dr. Lim is wonderful! She is thorough, kind, and concerned about my health. I appreciate all she has done to help me understand my condition and reassure me.

    March 11, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    Dr Lim has has knowledge about her patients, AND willingly shares her knowledge readily. Complex "issues" are explained in layman's terms and there are no questions that are not answered. Dr. Lim takes the time for questions and I have never felt rushed. Any time a facility, such as University of Utah, makes me feel as though I am the only person in the world that they are helping...I can't help but thinks this is the best "place" to be!

    February 27, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    Was very carrying and kind. Answered all my questions and help me understand my health and I know I am in good hands.

    February 27, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    I fully trust Dr Lim's treatment.

    February 25, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    Very knowledgeable very kind I am SO THANKFUL for Dr Lim

    January 08, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    Dr. LIM is a great doctor. She is very supportive and caring.

    See More Patient Comments

  • Dr. Ming Y. Lim is an Associate Professor in the Division of Hematology and Hematologic Malignancies at the University of Utah. She earned her medical degree at Cambridge University, England and completed her 2-year Foundation Training in the United Kingdom. She then completed residency in internal medicine at the Mayo Clinic Rochester and fellowship training in hematology and oncology at University of North Carolina at Chapel Hill. Her clinical interest lies in the field of hemostasis and thrombosis. Her research interest is focused on complications affecting people with congenital bleeding disorders, specifically persons with hemophilia with inhibitors and pregnant women with bleeding disorders.

    Dr. Lim is the Medical Director for the Utah Center for Bleeding & Clotting Disorders at University of Utah Health. Nationally, she serves as the Chair of the American Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Assessment Approval Committee, the Chair of the American Society of Hematology (ASH) Subcommittee on Stewardship and Systems-Based Hematology, and the Education Officer for the Hemostasis and Thrombosis Research Society (HTRS). She also serves on the National Bleeding Disorders Foundation (NBDF) Medical and Scientific Advisory Council (MASAC) and on the National Comprehensive Cancer Network (NCCN) Cancer-Associated Venous Thromboembolic Disease Panel.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Associate Professor (Clinical)
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    Educational Commission for Foreign Medical Graduates
    National Certification Board for Anticoagulation Providers

    Education history

    Graduate Training Clinical Research - Medical University of South Carolina M.S.
    Fellowship Hematology/Oncology - University of North Carolina at Chapel Hill School of Medicine Fellow
    Residency Internal Medicine - Mayo School of Graduate Medical Education Resident
    Diploma Palliative Medicine - Cardiff University School of Medicine Diploma
    Professional Medical Clinical Medicine - Cambridge University School of Clinical Medicine MB BChir
    Graduate Training Medical Sciences - Magdalene College, University of Cambridge M.A.

    Selected Publications

    Journal Article

    1. Parks AL, Jenkins SL, Vazquez SR, Swenson E, Lim MY, Moser KA, Witt DM (2025). The clot cases conference: a proposed model to enhance multidisciplinary thrombosis care. J Thromb Thrombolysis. (Read full article)
    2. Lim MY, Sivaloganathan V, Rodgers GM, Simonsen SE (2025). Development and validation of an algorithm to better identify pregnant women with inherited bleeding disorders within electronic health records. Thromb Res, 246, 109253. (Read full article)
    3. Fatola A, Evans MD, Brown J, Davis E, Johnson A, Antun AG, Farland AM, Woods R, Metjian A, Park YA, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Eubanks S, Akwaa F, Clover T, Kreuziger LB, Sadler JE, Sridharan M, Go RS, McCrae KR, Upreti HV, Lim MY, Kocher NK, Gangaraju R, Zheng XL, Raval JS, Masias C, Cataland SR, Mazepa M, Chaturvedi S (2024). Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era. Blood Adv, 9(2), 417-424. (Read full article)
    4. Streiff MB, Holmstrom B, Angelini D, Ashrani A, Buckner T, Diep R, Fertrin KY, Fogerty AE, Crestani NG, Gangaraju R, Rojas-Hernandez C, Goldhaber SZ, Ibrahim I, Kubal T, Leavitt AD, Lim M, Mann J, Mantha S, Morton C, Nester A, OBrien A, Ortel TL, Pine A, Pishko A, Ranade M, Salmasi A, Schaefer J, Williams E, Wool G, Wun T, Montgomery S, Nguyen J, Freedman-Cass D, Sliker B (2024). Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 22(7), 483-506. (Read full article)
    5. Moshirfar M, Reynolds JC, Moin KA, Lim MY, Stoakes IM, Hoopes PC (2024). Perioperative Recommendations for Corneal Refractive Surgery Patients With Inherited Bleeding Disorders. Cornea, 43(12), 1599-1607. (Read full article)
    6. Lim MY, Abou-Ismail MY (2024). Double-heterozygous FVL/PTGM: double the trouble. Blood, 143(23), 2347-2349. (Read full article)
    7. Abou-Ismail MY, Zhang C, Presson AP, Chaturvedi S, Antun AG, Farland AM, Woods R, Metjian A, Park YA, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Akwaa F, Clover T, Kreuziger LB, Sridharan M, Go RS, McCrae KR, Upreti HV, Gangaraju R, Kocher NK, Zheng XL, Raval JS, Masias C, Cataland SR, Johnson AD, Davis E, Evans MD, Mazepa M, Lim MY (2024). A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura. Res Pract Thromb Haemost, 8(3), 102388. (Read full article)
    8. Lim MY, Rodgers GM, Branch DW, Simonsen SE (2024). Targeting a higher plasma VWF level at time of delivery in pregnant individuals with von Willebrand disease: Outcomes at a single-institution cohort study. Haemophilia, 30(2), 470-477. (Read full article)
    9. Abou-Ismail MY, Zhang C, Presson AP, Chaturvedi S, Antun AG, Farland AM, Woods R, Metjian A, Park YA, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Akwaa F, Clover T, Baumann Kreuziger L, Sridharan M, Go RS, McCrae KR, Upreti HV, Gangaraju R, Kocher NK, Zheng XL, Raval JS, Masias C, Cataland SR, Johnson AD, Davis E, Evans MD, Mazepa M, Lim MY (2023). A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry. Blood Adv, 8(3), 620-623. (Read full article)
    10. Ragni MV, Callis J, Daoud N, Hu B, Manuel M, Santos J, Schwartz J, Friedman KD, Kouides P, Kuriakose P, Leavitt AD, Lim MY, Machin N, Recht M, Chrisentery-Singleton T (2023). Observational cohort study of long-term outcomes of liver transplantation in haemophilia. Haemophilia, 30(1), 87-97. (Read full article)
    11. Wheeler AP, Lim MY, Huguelet PS, Jaffray J, Staber JM, Funkhouser K, Carpenter SL, Weyand AC (2023). Trends in dedicated care for females with bleeding disorders within U.S. hemophilia treatment centers. Am J Hematol, 98(12), E399-E402. (Read full article)
    12. Cogan JC, McFarland MM, May JE, Lim MY (2023). Quality improvement approaches to heparin-induced thrombocytopenia: a scoping review. Res Pract Thromb Haemost, 7(7), 102219. (Read full article)
    13. Young A, Lim MY, Sanders J, Branch DW, Simonsen SE (2022). Pregnancy and Childbirth in Women with Bleeding Disorders: A Retrospective Cohort Study. Haemophilia, 29(1), 240-247. (Read full article)
    14. Montgomery HD, Agarwal AM, Lim MY (2022). A case of azathioprine-induced aplastic anemia. Int J Lab Hematol, 44(6), 1015-1016. (Read full article)
    15. Bruno AM, Allshouse AA, Campbell HM, Branch DW, Lim MY, Silver RM, Metz TD (2022). Weight-Based Compared with Fixed-Dose Enoxaparin Prophylaxis After Cesarean Delivery: A Randomized Controlled Trial. Obstet Gynecol, 140(4), 575-583. (Read full article)
    16. Chaturvedi S, Antun AG, Farland AM, Woods R, Metjian A, Park YA, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Akwaa F, Clover T, Baumann Kreuziger L, Sadler JE, Sridharan M, Go RS, McCrae KR, Upreti HV, Liu A, Lim MY, Gangaraju R, Zheng XL, Raval JS, Masias C, Cataland SR, Johnson A, Davis E, Evans MD, Mazepa MA, United States Thrombotic Microangiopathies Consortium (2022). Race, Rituximab, and Relapse in TTP. Blood, 140(12), 1335-1344. (Read full article)
    17. Simpson SJ, Lim MY, George TI, Rets A (2021). 36-year-old male with X-linked congenital sideroblastic anemia presenting as chronic microcytic anemia with iron overload. Int J Lab Hematol, 44(1), 69-71. (Read full article)

    Review

    1. Cogan JC, Burnett AE, Power-Hays A, Barnes GD, Lim MY (2025). Identifying and addressing underuse in hematologic care through systems-based hematology. [Review]. Res Pract Thromb Haemost, 9(4), 102881. (Read full article)
    2. La Mura V, Colombo M, Foster GR, Angeli P, Miesbach W, Klamroth R, Pierce GF, OMahony B, Lim MY, Hernandez-Gea V, Makris M, Peyvandi F (2024). The management of liver disease in people with congenital bleeding disorders: guidance from European Association for Haemophilia and Allied Disorders, European Haemophilia Consortium, ISTH, and World Federation of Hemophilia. [Review]. J Thromb Haemost, 22(12), 3629-3639. (Read full article)
    3. Branch DW, Lim MY (2023). How I Diagnose And Treat Antiphospholipid Syndrome In Pregnancy. [Review]. Blood, 143(9), 757-768. (Read full article)
    4. Lim MY, Abou-Ismail MY, Branch DW (2022). Differentiating and Managing Rare Thrombotic Microangiopathies During Pregnancy and Postpartum. [Review]. Obstet Gynecol, 141(1), 85-108. (Read full article)
    5. Elshoury A, Schaefer JK, Lim MY, Skalla DP, Streiff MB (2022). Update on Guidelines for the Prevention of Cancer-Associated Thrombosis. [Review]. J Natl Compr Canc Netw, 1-8. (Read full article)
    6. Thomas VM, Abou-Ismail MY, Lim MY (2021). Off-label Use of Emicizumab in Persons with Acquired Haemophilia A and von Willebrand Disease: A Scoping Review of the Literature. [Review]. Haemophilia, 28(1), 4-17. (Read full article)
    7. Baljevic M, Sborov DW, Lim MY, Hillengass J, Martin T, Castillo JJ, Streiff MB, Kumar SK, Callander NS (2021). Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma. [Review]. J Natl Compr Canc Netw, 20(1), 91-95. (Read full article)
    8. Lim MY (2021). How Do We Optimally Utilize Factor Concentrates in Persons with Hemophilia? [Review]. Hematology Am Soc Hematol Educ Program, 2021(1), 206-214. (Read full article)

    Case Report

    1. Gleichgerrcht E, Lim MY, Turan TN (2017). Cerebral Venous Sinus Thrombosis Due to Low-molecular-weight Heparin-induced Thrombocytopenia. Neurologist, 22(6), 241-244. (Read full article)